Pliant Therapeutics (NASDAQ:PLRX) Given New $51.00 Price Target at Oppenheimer

Pliant Therapeutics (NASDAQ:PLRX – Get Rating) had its price objective raised by Oppenheimer from $44.00 to $51.00 in a research note released on Wednesday morning, The Fly reports. Other research analysts also recently issued research reports about the stock. Needham & Company LLC reaffirmed a buy rating and issued a $45.00 price target on shares […]

Related Keywords

United States ,Mike Ouimette ,Keith Lamont Cummings ,Needham Company ,Vanguard Group Inc ,Securities Exchange Commission ,Jennison Associates ,Cantor Fitzgerald ,Blackrock Inc ,Vr Adviser ,Nasdaq ,Jpmorgan Chase Co ,Pliant Therapeutics Inc ,Pricet Rowe Associates Inc ,Pliant Therapeutics ,Get Rating ,General Counsel Mike Ouimette ,Exchange Commission ,Lamont Cummings ,Pliant Therapeutics Daily ,Nasdaq Plrx ,Plrx ,Medical ,Boost Price Target ,Oppenheimer Holdings Inc ,